US pharmaceutical major Bristol-Myers Squibb (BMS, NYSE: BMY) provided an update on the RELATIVITY-098 study for its Opdualag (nivolumab and relatlimab-rmbw). The Phase III study, which evaluated the drug as an adjuvant treatment for patients with completely resected stage III-IV melanoma, failed to meet its primary endpoint of recurrence-free survival (RFS).
Drug Background
Opdualag is an immunotherapy combination of the programmed death-1 (PD-1) inhibitor nivolumab and the lymphocyte activation gene 3 (LAG-3) blocking antibody relatlimab. The drug first received FDA approval in 2022 for the treatment of unresectable metastatic melanoma.
Study Details
The RELATIVITY-098 study aimed to assess the efficacy of Opdualag in preventing recurrence in patients with stage III-IV melanoma who had undergone complete resection. Despite the failure to meet the primary endpoint, the company may continue to analyze the data to explore potential secondary endpoints or subgroups where the drug may show benefit.-Fineline Info & Tech
Leave a Reply